Method Of Altering The Differentiation State Of The Cell Patents (Class 435/377)
  • Patent number: 11124765
    Abstract: The present invention relates to methods for deriving human hematopoietic progenitors, primitive macrophages, and microglial cells from human pluripotent stem cells. In particular, provided herein are highly efficient and reproducible methods of obtaining human primitive macrophages and microglia from human pluripotent stem cells, where the primitive macrophages and microglia can be suitable for clinically relevant therapeutic applications.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: September 21, 2021
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: James A. Thomson, Nicholas E. Propson, Michael P. Schwartz, Zhonggang Hou, Gene I. Uenishi, Igor I. Slukvin, William L. Murphy, Jue Zhang
  • Patent number: 11104883
    Abstract: Disclosed herein are methods, compositions, kits, and agents useful for inducing ? cell maturation, and isolated populations of SC-? cells for use in various applications, such as cell therapy.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: August 31, 2021
    Assignee: President and Fellows of Harvard College
    Inventors: Quinn P. Peterson, Felicia J. Pagliuca, Douglas A. Melton, Jeffrey R. Millman, Michael Saris Segel, Mads Gurtler
  • Patent number: 11078463
    Abstract: Disclosed herein are methods, compositions, kits, and agents useful for inducing ? cell maturation, and isolated populations of SC-? cells for use in various applications, such as cell therapy.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: August 3, 2021
    Assignee: President and Fellows of Harvard College
    Inventors: Quinn P. Peterson, Felicia J. Pagliuca, Douglas A. Melton, Jeffrey R. Millman, Michael Saris Segel, Mads Gurtler
  • Patent number: 11028370
    Abstract: The present invention provides compositions and methods for reprogramming somatic cells using purified RNA preparations comprising single-strand mRNA encoding an iPS cell induction factor. The purified RNA preparations are preferably substantially free of RNA contaminant molecules that: i) would activate an immune response in the somatic cells, ii) would decrease expression of the single-stranded mRNA in the somatic cells, and/or iii) active RNA sensors in the somatic cells. In certain embodiments, the purified RNA preparations are substantially free of partial mRNAs, double-stranded RNAs, un-capped RNA molecules, and/or single-stranded run-on mRNAs.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: June 8, 2021
    Inventors: Katalin Kariko, Drew Weissman, Gary Dahl, Anthony Person, Judith Meis, Jerome Jendrisak
  • Patent number: 11001808
    Abstract: The present invention is directed towards methods of culturing non-keratinocyte epithelial cells, with the methods comprising culturing non-keratinocyte epithelial cells in the presence of feeder cells and a calcium-containing medium while inhibiting the activity of Rho kinase (ROCK) in the feeder cell, the non-keratinocyte epithelial cells or both during culturing.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: May 11, 2021
    Assignee: Georgetown University
    Inventors: Richard Schlegel, Xuefeng Liu
  • Patent number: 10945598
    Abstract: A method for assisting corneal severity identification, the method comprising obtaining a corneal configuration data set of a cornea to be examined by a tomography such as an optical coherence tomography; visualizing the corneal configuration data set of the cornea to be examined along with a number of pre-existing corneal configuration data sets of disorder corneas, disorder-suspect corneas and normal corneas obtained by the tomography using t-distributed Stochastic Neighbor Embedding in a two or three dimensional map, and judging corneal severity from the map.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: March 16, 2021
    Inventors: Siamak Yousefi, Hidenori Takahashi, Takahiko Hayashi
  • Patent number: 10905465
    Abstract: A delivery device for delivering an implantable leadless pacing device may include a catheter shaft a distal holding section for receiving the implantable leadless pacing device. In some cases, the delivery device may include a flow-sensing device to determine a pressure or flow-rate of a fluid within the distal holding section. Also included may be a handle assembly and a deployment mechanism to deploy the implantable leadless pacing device.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: February 2, 2021
    Assignee: CARDIAC PACEMAKERS, INC.
    Inventors: Allan Charles Shuros, Brian Soltis, Yinghong Yu, Arjun D. Sharma
  • Patent number: 10858628
    Abstract: The invention provides culture platforms, cell media, and methods of differentiating pluripotent cells into hematopoietic cells. The invention further provides pluripotent stem cell-derived hematopoietic cells generated using the culture platforms and methods disclosed herein, which enable feed-free, monolayer culturing and in the absence of EB formation. Specifically, pluripotent stem cell-derived hematopoietic cell of this invention include, and not limited to, iHSC, definitive hemogenic endothelium, hematopoietic multipotent progenitors, T cell progenitors, NK cell progenitors, T cells, NK cells, NKT cells and B cells.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: December 8, 2020
    Assignee: Fate Therapeutics, Inc.
    Inventors: Bahram Valamehr, Raedun Clarke, Ryan Bjordahl
  • Patent number: 10844356
    Abstract: The invention provides cell culture conditions for culturing stem cells, including feeder-free conditions for generating and culturing human induced pluripotent stem cells (iPSCs). More particularly, the invention provides a culture platform that allows long-term culture of pluripotent cells in a feeder-free environment; reprogramming of cells in a feeder-free environment; single-cell dissociation of pluripotent cells; cell sorting of pluripotent cells; maintenance of an undifferentiated status; improved efficiency of reprogramming; and generation of a naïve pluripotent cell.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: November 24, 2020
    Assignee: FATE THERAPEUTICS, INC.
    Inventors: Bahram Valamehr, Ramzey Abujarour, Peter Flynn
  • Patent number: 10836997
    Abstract: Provided is a method of differentiating a pluripotent stem cell of mammalian origin into a desired cell type by predicting the direction of cell differentiation to be caused by induction of expression of a transcription factor. A human gene expression correlation matrix using human cells has been newly created, and further, it has been confirmed that human pluripotent stem cells can be differentiated into a desired cell type by introducing, into the human pluripotent stem cells, a transcription factor cocktail selected from the matrix.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: November 17, 2020
    Assignee: KEIO UNIVERSITY
    Inventor: Minoru Ko
  • Patent number: 10829733
    Abstract: Compositions and processes for culturing human stem cells in vitro in an undifferentiated state are disclosed. In this regard, human embryonic stem cells proliferated and maintained their pluripotency when cultured on plates coated with recombinant laminin-10 (laminin-511).
    Type: Grant
    Filed: March 17, 2010
    Date of Patent: November 10, 2020
    Assignee: BIOLAMINA AB
    Inventors: Karl Tryggvason, Sergey Rodin, Anna Domogatskaya
  • Patent number: 10767162
    Abstract: Described herein are methods relating to the differentiation of stem cells to more differentiated phenotypes, e.g. to terminally differentiated cell types and/or precursors thereof. In some embodiments, the methods relate to contacting the stem cells with differentiation factors and halting the cell cycle, thereby increasing the rate of differentiation.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: September 8, 2020
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Victor Chun Li, Marc W. Kirschner
  • Patent number: 10760050
    Abstract: The present invention provides a method for producing a retinal pigment epithelial cell, including (1) a first step of subjecting pluripotent stem cells to floating culture in a serum-free medium to form an aggregate of pluripotent stem cells, (2) a second step of subjecting the aggregate formed in step (1) to floating culture in a serum-free medium or serum-containing medium each being free of a substance acting on the Sonic hedgehog signal transduction pathway and containing a substance acting on the BMP signal transduction pathway, thereby obtaining an aggregate containing retinal progenitor cells, and (3) a third step of subjecting the aggregate formed in step (2) to floating culture in a serum-free medium or serum-containing medium each being free of a substance acting on the Sonic hedgehog signal transduction pathway and a substance acting on the BMP signal transduction pathway and containing a substance acting on the Wnt signal pathway, thereby obtaining an aggregate containing retinal pigment epithel
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: September 1, 2020
    Assignees: SUMITOMO CHEMICAL COMPANY, LIMITED, RIKEN
    Inventors: Tokushige Nakano, Yoshiki Sasai, Chikafumi Ozone
  • Patent number: 10760049
    Abstract: The present invention relates to the generation of neural cells from undifferentiated human embryonic stem cells. In particular it relates to directing the differentiation of human ES cells into neural progenitors and neural cells and the production of functioning neural cells and/or neural cells of a specific type. The invention also includes the use of these cells for the treatment of neurological conditions such as Parkinson's disease.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: September 1, 2020
    Assignee: ES Cell International PTE Ltd.
    Inventor: Benjamin Eithan Reubinoff
  • Patent number: 10731133
    Abstract: A method for acquiring and producing high-purity renal progenitor cells from a renal progenitor cell population into which pluripotent stem cells are induced to differentiate, by identifying a cell surface antigen marker specific to renal progenitor cells. The disclosed method may include, for example, the steps of: (i) culturing the pluripotent stem cells under conditions that induce differentiation into renal progenitor cells; and (ii) sorting a cell population from the cells obtained at step (i), by using at least one cell surface marker selected from the group consisting of CD9(?), CD55(?), CD106(+), CD140a(+), CD140b(+), CD165(+), CD271(+) and CD326(?).
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: August 4, 2020
    Assignees: Astellas Pharma Inc., Kyoto University
    Inventors: Tatsuya Kawamoto, Yukiko Yamagishi, Kenji Osafune
  • Patent number: 10729723
    Abstract: An object of the present invention is to provide a pluripotent cell having high safety in application to regenerative medicine, and a method for production thereof. Another object of the present invention is to provide a pluripotent cell, particularly, having less concern for safety, such as a problem of cancerization of a cell, and the presence of bacteria in a cell, and a method for production thereof. According to the present invention, there is provided a method for producing a pluripotent cell from a somatic cell. The method comprises a step of inducing reprogramming of a somatic cell, by contacting the cell with a ribosome fraction derived from an organism. Further, according to the present invention, there is provided a composition for inducing reprogramming of a cell, comprising a ribosome fraction derived from an organism.
    Type: Grant
    Filed: May 11, 2015
    Date of Patent: August 4, 2020
    Assignee: NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
    Inventors: Kunimasa Ohta, Naofumi Ito
  • Patent number: 10722554
    Abstract: The invention relates to the use of a homeoprotein of the bicoid family, in particular of the Otx family, for enhancing the survival of cultivated retinal ganglion neurones, and for preventing or treating ganglion neuron degeneration particularly occurring in glaucoma.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: July 28, 2020
    Assignees: Centre National de la Recherche Scientifique, Ecole Normale Superieure
    Inventors: Alain Prochiantz, Kenneth Lee Moya
  • Patent number: 10724000
    Abstract: This application relates to a method for differentiating somatic cells into multi-competent neural crest cells based on linked steps of chemically defined medium inductions. Neural crest cells are able to differentiate into numerous cell types like Schwann cells, chondrocytes, smooth muscle cells or adipocytes.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: July 28, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Martin Graf, Roberto Iacone, Eva Christina Thoma
  • Patent number: 10711243
    Abstract: The present invention relates to the field of stem cell biology, in particular the lineage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hESC) in addition to nonembryonic human induced pluripotent stem cells (hiPSC), somatic stem cells, stem cells from patients with a disease, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hESC and/or hiPSC into floor plate midbrain progenitor cells and then further into large populations of midbrain fate FOXA2+LMX1A+TH+ dopamine (DA) neurons using novel culture conditions.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: July 14, 2020
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Lorenz Studer, Jae-Won Shim, Sonja Kriks
  • Patent number: 10689614
    Abstract: Provided is a cell culture support, which is a support for attaching and culturing cells, and which includes: a fibrous web which is made by accumulating fibers of a biodegradable polymer and on which a plurality of pores are formed; and a plurality of beads formed on the fibers to secure spaces through which the cells penetrate into the fibrous web and grow therein.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: June 23, 2020
    Assignee: AMOLIFESCIENCE CO., LTD.
    Inventors: In Yong Seo, Seung Hoon Lee, Song Hee Koo, Ji Hyun Lee
  • Patent number: 10689615
    Abstract: A temperature-responsive substrate having on its surface a layer containing at least one polymer, the at least one polymer being responsive to temperature and containing a fluorine-containing monomer-derived unit. Also disclosed is a polymer and composition for use in producing the substrate, as well as methods for producing, using and evaluating the substrate.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: June 23, 2020
    Assignee: DAIKIN INDUSTRIES, LTD.
    Inventors: Masamichi Morita, Kouji Kubota, Yoshiko Koizumi, Hiroki Yamaguchi
  • Patent number: 10683486
    Abstract: Methods for producing hepatocytes from pluripotent human stem cells are disclosed herein. The stem cells are plated on a cell culture substrate comprising two laminins. The stem cells are then exposed to different cell culture mediums to induce differentiation. The resulting hepatocytes have higher metabolic capacity compared to hepatocytes cultured on different substrates.
    Type: Grant
    Filed: October 29, 2016
    Date of Patent: June 16, 2020
    Assignees: BIOLAMINA AB, THE UNIVERSITY OF EDINBURGH
    Inventors: Louise Kristina Hagbard, Carl Gunnar Jesper Ericsson, Katherine Rachel Cameron, David Colin Hay, Stuart John Forbes, Hassan Rashidi
  • Patent number: 10669529
    Abstract: Provided is a method for producing vascular endothelial cells from pluripotent stem cells, the method comprising the following steps (i) to (iii): (i) a step of culturing pluripotent stem cells in a culture medium comprising a BMP, on a culture vessel coated with a first matrix, to produce mesodermal progenitor cells; (ii) a step of dissociating the resulting cells into single cells; and (iii) a step of culturing the resulting cells in a culture medium comprising VEGF, on a culture vessel coated with a second matrix selected from the group consisting of laminin-411 or a fragment thereof, laminin-511 or a fragment thereof, Matrigel, type IV collagen and fibronectin.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: June 2, 2020
    Assignees: Kyoto University, Osaka University
    Inventors: Tatsutoshi Nakahata, Megumu Saito, Akira Niwa, Ryo Ota, Kiyotoshi Sekiguchi
  • Patent number: 10655105
    Abstract: The present invention relates to a method for preparing highly pure pancreatic progenitor cells by using pluripotent stem cells such as ES cells or iPS cells as a source, inducing their differentiation into pancreatic progenitor cells, and culturing and proliferating the pancreatic progenitor cells. Specifically, the present invention relates to a method for proliferation of pancreatic progenitor cells, comprising the step of culturing the pancreatic progenitor cells in a medium containing (i) an EGF signal transduction activator and/or an FGF signal transduction activator and (ii) a ROCK inhibitor.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: May 19, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventor: Yuya Kunisada
  • Patent number: 10632154
    Abstract: The present invention relates to the use of insulin-producing cells encapsulated in silanized hydroxypropyl methylcellulose (Si-HPMC) for the treatment of type 1 diabetes. Methods and kits are also provided for restoring and/or maintaining euglycemia in type 1 diabetic patients and in type 1 prediabetic patients.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: April 28, 2020
    Assignees: Ecole Nationale Veterinaire, Chu Nantes, Universite de Nantes, Institute National de la Sante et de la Recherche Medicale
    Inventors: Jean-Marie Bach, Mathilde Mosser, Apolline Salama, Anne Moure, Xavier Leveque, Pierre Weiss, Jérôme Guicheux, Cécile Boyer, David Riochet
  • Patent number: 10626370
    Abstract: Process for carrying out an in vitro biochemical reaction for preparing a cell suspension suitable for application to the skin of a patient.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: April 21, 2020
    Assignee: LABORATOIRES GENEVRIER
    Inventors: Dominique Vacher, Jean-Noel Gouze
  • Patent number: 10626369
    Abstract: The present disclosure relates to methods of producing a preparation of CD140a/PDGFR? positive cells from pluripotent cells, where the preparation comprises oligodendrocyte progenitor cells co-expressing OLIG2 and CD140a/PDGFR?. The cell preparation has an in vivo myelination efficiency that is equal to or greater than the in vivo myelination efficiency of a preparation of A2B5+/PSA-NCAM? sorted fetal human tissue derived oligodendrocyte progenitor cells. Methods of enriching and therapeutic uses of the disclosed cell preparation are also described.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: April 21, 2020
    Assignee: University of Rochester
    Inventors: Steven A. Goldman, Su Wang
  • Patent number: 10612094
    Abstract: The present invention provides genetic markers for identifying engraftable human cardiac ventricular progenitor cells. The engraftment markers of the invention include angiogenic markers and extracellular matrix markers. Human ventricular progenitor cells expressing these markers are capable of forming ventricular tissue in vivo that is vascularized and supported by an extracellular matrix. Methods of engrafting human cardiac ventricular progenitor cells by transplanting into a subject progenitor cells that express the engraftment markers are also provided.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: April 7, 2020
    Assignee: Procella Therapeutics AB
    Inventors: Chuen Yan Leung, Jonathan Clarke, Jiejia Xu, Federica Santoro, Makoto Sahara, Kenneth R. Chien
  • Patent number: 10590390
    Abstract: The present invention relates to a method for preparing highly pure pancreatic progenitor cells by using pluripotent stem cells such as ES cells or iPS cells as a source, inducing their differentiation into pancreatic progenitor cells, and culturing and proliferating the pancreatic progenitor cells. Specifically, the present invention relates to a method for proliferation of pancreatic progenitor cells, comprising the step of culturing the pancreatic progenitor cells in a medium containing (i) an EGF signal transduction activator and/or an FGF signal transduction activator and (ii) a ROCK inhibitor.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: March 17, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventor: Yuya Kunisada
  • Patent number: 10584313
    Abstract: The present invention relates generally to the field of somatic cell nuclear transfer (SCNT) and to the creation of cloned animals and cells. The disclosure relates to a method of cloning a mammal, obtaining pluripotent cells such as embryonic stem cells, or for reprogramming a mammalian cell using an oocyte and a fertilized embryo.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: March 10, 2020
    Assignee: Astellas Institute for Regenerative Medicine
    Inventors: Robert P. Lanza, Young Gie Chung
  • Patent number: 10568852
    Abstract: The present invention relates to compositions comprising at least two different active compounds and the use of such combination compositions in medicine, in particular in methods for treating obesity and obesity-related disorders and/or in methods for inhibiting weight gain.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: February 25, 2020
    Assignee: HELMHOLTZ ZENTRUM MUNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH)
    Inventors: Timo Dirk Mueller, Matthias Tschoep, Christoffer Clemmensen, Brian Finan
  • Patent number: 10568883
    Abstract: Method and compositions for inducing the self-renewal of stem/progenitor supporting cells comprised by a cochlear cell population, including inducing the stem/progenitor cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into hair cells.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: February 25, 2020
    Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Jeffrey M. Karp, Robert S. Langer, Xiaolei Yin, Nitin Joshi
  • Patent number: 10527631
    Abstract: Methods and compositions are provided for the selective activation of a BMP-dependent response in certain cell types. Methods include identifying a ligand or ligand combinations as well as cell receptor profiles that result in selectively activating a ligand-dependent response through interactions with ligand receptors on a first cell type that do not activate the ligand-dependent response in a second cell type.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: January 7, 2020
    Assignee: California Institute of Technology
    Inventors: Yaron E. Antebi, James Linton, Michael Elowitz, Heidi Klumpe
  • Patent number: 10519422
    Abstract: The invention relates to a method of producing a retinal pigment epithelial cell from a human pluripotent stem cell, and a method of treating or preventing a retinal disease by using the produced cell. The retinal pigment epithelial cell is prepared by (a) inducing differentiation of a human pluripotent stem cell into a pigment cell by adhesion cultivation of a human pluripotent stem cell in a medium containing a Nodal signal inhibitor and a Wnt signal inhibitor in the absence of a feeder cell to give a culture containing the pigment cell, (b) subjecting the obtained culture to further adhesion culture to give a culture containing a pigment cell colony, and (c) isolating the pigment cell from the obtained culture and culturing the cell to give a retinal pigment epithelial cell.
    Type: Grant
    Filed: February 29, 2012
    Date of Patent: December 31, 2019
    Assignee: RIKEN
    Inventors: Masayo Takahashi, Satoshi Okamoto, Noriko Sakai
  • Patent number: 10513685
    Abstract: Provided is a method that achieves control of embryoid body size and can induce differentiation in a state where the embryoid body size is controlled, by using a cell culture chamber having a plurality of microchambers formed therein. A culture method for causing differentiation of pluripotent mammalian cells uses a cell culture chamber (10) having a plurality of microchambers (11) formed on a culture surface. The cell culture chamber (10) has a culture surface formed of spaces in which the microchambers (11) have a space structure with a height of 10 ?m to 500 ?m and a bottom area of 100 ?m2 to 1 mm2. The culture method for causing differentiation of pluripotent mammalian cells includes culturing pluripotent mammalian cells to obtain a cell population at least partially differentiated into endoderm lineage cells, by using the cell culture chambers (10).
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: December 24, 2019
    Assignees: CORNING INCORPORATED, PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY
    Inventors: Yoko Itchoda, Go Tazaki, Masaya Hosoda, Motohiro Fukuda, Hideki Taniguchi, Yun-Wen Zheng, Keisuke Sekine
  • Patent number: 10513688
    Abstract: Methods of generating cardiomyocytes from induced pluripotent stem cells (IPSCs) are provided. More specifically, the present disclosure relates to methods of generating cardiomyocytes from iPSCs using electrical stimulation. In some aspects, uses of such cells for therapeutics and in methods of treatment are provided.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: December 24, 2019
    Assignee: University of Cincinnati
    Inventors: Yi-Gang Wang, Ha Won Kim, Ruilian Ma
  • Patent number: 10501724
    Abstract: The present invention provides a method for producing a retinal progenitor cell, including (1) a first step of subjecting pluripotent stem cells to floating culture in a serum-free medium to form an aggregate of pluripotent stem cells, and (2) a second step of subjecting the aggregate formed in step (1) to floating culture in a serum-free medium or serum-containing medium each being free of a substance acting on the Sonic hedgehog signal transduction pathway but containing a substance acting on the BMP signal transduction pathway, thereby obtaining an aggregate containing retinal progenitor cells.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: December 10, 2019
    Assignees: SUMITOMO CHEMICAL COMPANY, LIMITED, RIKEN
    Inventors: Tokushige Nakano, Yoshiki Sasai, Chikafumi Ozone
  • Patent number: 10494608
    Abstract: The present invention relates to a method for isolating bona fide pancreatic progenitor cells and to cell populations enriched for bona fide pancreatic progenitor cells.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: December 3, 2019
    Assignee: University of Copenhagen
    Inventors: Jacqueline Ameri, Henrik Semb
  • Patent number: 10472610
    Abstract: Provided is a method for generating pancreatic bud cells, having the step of culturing PDX1+/NKX6.1? cells in a medium containing KGF, EGF and a BMP inhibitor. The culturing step may be performed in suspension cultures or in adherent cultures. When the cells are cultured in adherent cultures, the cells may be cultured in a medium further containing a ROCK inhibitor or a nonmuscle myosin II inhibitor.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: November 12, 2019
    Assignee: KYOTO UNIVERSITY
    Inventors: Kenji Osafune, Taro Toyoda
  • Patent number: 10457916
    Abstract: It is an object of the present invention to provide a method for efficiently directing differentiation into insulin-producing cells in a xeno-free culture system.
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: October 29, 2019
    Assignee: Tokyo Institute of Technology
    Inventors: Shoen Kume, Nobuaki Shiraki
  • Patent number: 10426799
    Abstract: Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.
    Type: Grant
    Filed: December 21, 2013
    Date of Patent: October 1, 2019
    Assignee: Astellas Institute for Regenerative Medicine
    Inventors: Qiang Feng, Shi-Jiang Lu, Robert P. Lanza
  • Patent number: 10421961
    Abstract: Some embodiments of the invention comprise methods, systems, and compositions to selectively induce, whether in vitro or in vivo, the neuronal differentiation of multipotent stromal cells through the application of microRNAs, including but not limited to miRNA-124, miRNA-137 and/or miRNA-9* expression products of those miRNAs, and molecules and compositions containing functional elements of those miRNAs. Some embodiments of the invention also comprise the therapeutic administration and use of such induced cells to treat mammalian injuries and diseases, including but not limited to, nervous system injuries or diseases that may otherwise result in decreased cell or system function.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: September 24, 2019
    Assignee: EXOSTEM BIOTEC LTD
    Inventors: Chaya Brodie, Shimon Slavin
  • Patent number: 10420803
    Abstract: Cell populations of intestinal midgut endoderm cells and methods of generating the cells expressing markers characteristic of intestinal endoderm lineage are disclosed. Methods of treating conditions such as diabetes are also disclosed.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: September 24, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: Sebastian Rieck, Alireza Rezania
  • Patent number: 10421942
    Abstract: Disclosed herein are cell cultures comprising definitive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified definitive endoderm cells as well as methods for enriching, isolating and purifying definitive endoderm cells from other cell types.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: September 24, 2019
    Assignee: ViaCyte, Inc.
    Inventors: Kevin Allen D'Amour, Alan D. Agulnick, Emmanuel E. Baetge
  • Patent number: 10392602
    Abstract: Provided is a method of producing a lacrimal gland epithelial cell from a pluripotent stem cell, a lacrimal gland epithelial cell produced by the method, and a reagent kit for inducing differentiation from a pluripotent stem cell into a lacrimal gland epithelial cell. A method of producing a lacrimal gland epithelial cell includes the following step A: Step A: a step including increasing expression of Pax6 gene in a pluripotent stem cell or transfecting PAX6 protein thereinto, and increasing expression of Foxc1 gene or Foxp1 gene in the pluripotent stem cell or transfecting FOXC1 protein or FOXP1 protein thereinto.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: August 27, 2019
    Assignee: KEIO UNIVERSITY
    Inventors: Masatoshi Hirayama, Minoru Ko
  • Patent number: 10294449
    Abstract: A substrate for culturing cells that includes at least one fiber scaffold adapted to be contained within a disposable or non-disposable bioreactor, wherein the fiber scaffold further includes polymer fibers that have been created by electrospinning, and wherein the orientation of the fibers in the scaffold relative to one another is generally parallel, random, or both.
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: May 21, 2019
    Assignee: NANOFIBER SOLUTIONS, LLC
    Inventor: Jed K. Johnson
  • Patent number: 10260041
    Abstract: The present invention relates generally to the field of cell biology of stem cells, more specifically the directed differentiation of pluripotent or multipotent stem cells, including human embryonic stem cells (hESC), somatic stem cells, and induced human pluripotent stem cells (hiPSC) using novel culture conditions. Specifically, methods are provided for obtaining neural tissue, floor plate cells, and placode including induction of neural plate development in hESCs for obtaining midbrain dopamine (DA) neurons, motorneurons, and sensory neurons. Further, neural plate tissue obtained using methods of the present inventions are contemplated for use in co-cultures with other tissues as inducers for shifting differentiation pathways, i.e. patterning.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: April 16, 2019
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Stuart Chambers, Lorenz Studer
  • Patent number: 10226487
    Abstract: The present invention relates to methods for deriving multipotent Isl1+ cells (i.e. methods for inducing a cell to enter a multipotent Isl1+ lineage), methods for differentiating Isl1+ cells to cardiac cells, cells obtainable by such methods, kits and compositions for carrying out the methods in accordance with the invention, and also medical applications and pharmaceutical compositions of said cells.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: March 12, 2019
    Assignee: IsletOne AB
    Inventors: Karl-Henrik Grinnemo, Oscar Simonson, Matthias Corbascio, Christer Sylvén, Eva Wärdell
  • Patent number: 10202579
    Abstract: The present invention relates to the directed differentiation of mammalian pluripotent stem cells, especially human pluripotent stem (hPS) cells, into endodermal cells. In particular, the present invention relates to the treatment of mammalian pluripotent stem cells, especially hPS cells, with a DNA demethylating agent while undergoing differentiation into endodermal. The inventors have, as disclosed herein, found that exposing differentiating mammalian pluripotent stem cells, especially hPS cells, to a DNA demethylating agent leads to an improved morphology and improved yield of endodermal cells. The treatment with a DNA de-methylating agent also leads to a significant down-regulation of expression of the stem cell marker Oct4 and to an improved expression of endoderm specific markers, notably sox17, cxcr4 and hhex.
    Type: Grant
    Filed: November 28, 2013
    Date of Patent: February 12, 2019
    Assignee: Takara Bio Europe AB
    Inventors: Barbara Küppers-Munther, Josefina Edsbagge
  • Patent number: 10202580
    Abstract: The present invention provides a method for producing adult oligodendrocyte progenitor cells from proliferative oligodendrocyte progenitor cells, and a pharmaceutical composition having for an active ingredient thereof adult OPC produced according to that method. The method for producing adult OPC of the present invention is characterized by inducing proliferating OPC to differentiate into adult OPC by culturing in the presence of a ligand of a thyroid hormone receptor or retinoic acid receptor in a low oxygen environment. The present invention further provides adult OPC produced according to the production method of the present invention, and a pharmaceutical composition having these adult OPC as an active ingredient thereof.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: February 12, 2019
    Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCY
    Inventors: Makoto Suematsu, Yasuhito Tokumoto, Shinpei Tamaki